Which drugs are used to prevent migraine headaches? (Select all that apply).

Schizophrenia is characterized by a range of symptoms grouped into positive, negative, and cognitive domains. Positive symptoms represent an excess or distortion of normal function, often involving psychosis and behavioral dysregulation. These symptoms are the most noticeable and include hallucinations, delusions, and disorganized thinking or behavior. They reflect an overactivation of dopamine pathways in certain brain regions.

Rationale:
A. Hallucinations, delusions, and paranoia are classic positive symptoms because they represent an added or distorted perception of reality. Hallucinations involve sensory experiences without external stimuli, while delusions are fixed false beliefs. Paranoia reflects persecutory thought content and is a common psychotic feature in schizophrenia.

B. Social and emotional withdrawal are negative symptoms, reflecting a reduction or loss of normal functioning. These include diminished emotional expression and reduced engagement in social interactions. They are associated with poor long-term functional outcomes rather than psychotic overactivity.

C. Combativeness and agitation can occur during acute psychotic episodes and are considered behavioral manifestations of positive symptoms. They are often driven by hallucinations, delusional beliefs, or severe thought disorganization. These behaviors reflect an active distortion of reality rather than loss of function.

D. Poor insight, poor judgment, and poor self-care are categorized as cognitive or functional impairments rather than positive symptoms. These reflect deficits in executive functioning and awareness of illness. They contribute significantly to impaired daily functioning but are not psychotic additions.

E. Disordered and disorganized speech is a positive symptom because it reflects disorganized thinking processes. This may include tangentiality, derailment, or incoherent speech patterns. It results from impaired thought organization associated with dopamine dysregulation in schizophrenia.

F. Lack of motivation, poverty of speech, and blunted affect are negative symptoms. They represent a decrease in normal emotional and behavioral expression. These symptoms often persist longer than positive symptoms and are more resistant to treatment, contributing to long-term disability.

Therapeutic drug monitoring is essential when using lithium because it has a narrow therapeutic index and a high risk of toxicity. Plasma levels must be carefully maintained within a defined therapeutic range to ensure effectiveness in mood stabilization while preventing adverse effects. Levels are routinely checked to guide dosing and prevent accumulation. Toxic effects become more likely as serum concentrations rise above the safe threshold.

Rationale:
A. Lithium levels should generally be kept below 1.5 mEq/L because concentrations above this range are associated with toxicity. At higher levels, patients may develop neurologic, gastrointestinal, and cardiovascular symptoms that can rapidly progress to severe toxicity. Maintaining levels below this threshold reduces the risk of serious complications.

B. 0.4 mEq/L is below the therapeutic range and would likely be ineffective for mood stabilization in Lithium therapy. Subtherapeutic levels may result in poor control of manic or depressive symptoms and increase the risk of relapse.

C. 0.2 mEq/L is significantly below therapeutic levels and is insufficient for clinical efficacy. At this concentration, lithium would not provide adequate mood stabilization or prophylaxis against bipolar episodes. It is far under the expected therapeutic range.

D. 0.8 mEq/L represents a typical maintenance therapeutic level rather than a maximum limit. Lithium is often maintained between approximately 0.6–1.2 mEq/L depending on clinical indication and patient response. This reflects a target range, not an upper toxicity threshold.